Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

Item
http://www.wikidata.org/entity/Q28247667
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Accuracy of 177Lu activity quantification in SPECT imaging: a phantom studyRole of tumor microenvironment in tumorigenesis.Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour.Chemotherapy in NETs: When and how.Deadtime effects in quantification of 177Lu activity for radionuclide therapy.The Evolution of Neuroendocrine Tumor Treatment reflected by ENETS Guidelines.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860

Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

Item
http://www.wikidata.org/entity/Q28247667
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@ast
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@en
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@nl
type
label
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@ast
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@en
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@nl
prefLabel
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@ast
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@en
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Favourable outcomes of (177)Lu ...... DG-avid neuroendocrine tumours
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698